DNLI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DNLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Denali Therapeutics's share price for the quarter that ended in Dec. 2024 was $20.38. Denali Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 144.22 Mil. Therefore, Denali Therapeutics's market cap for the quarter that ended in Dec. 2024 was $2,939.22 Mil.
Denali Therapeutics's quarterly market cap increased from Jun. 2024 ($3,323.34 Mil) to Sep. 2024 ($4,190.06 Mil) but then declined from Sep. 2024 ($4,190.06 Mil) to Dec. 2024 ($2,939.22 Mil).
Denali Therapeutics's annual market cap declined from Dec. 2022 ($3,781.21 Mil) to Dec. 2023 ($2,969.74 Mil) and declined from Dec. 2023 ($2,969.74 Mil) to Dec. 2024 ($2,939.22 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Denali Therapeutics's Enterprise Value for Today is $1,416.39 Mil.
The historical data trend for Denali Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Market Cap | Get a 7-Day Free Trial |
![]() |
![]() |
10,095.68 | 5,453.82 | 3,781.21 | 2,969.74 | 2,939.22 |
Denali Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Market Cap | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
2,969.74 | 2,924.37 | 3,323.34 | 4,190.06 | 2,939.22 |
For the Biotechnology subindustry, Denali Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Denali Therapeutics's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
Market Cap (A: Dec. 2024 ) | = | Share Price (A: Dec. 2024 ) | * | Shares Outstanding (EOP) (A: Dec. 2024 ) |
= | $20.38 | * | 144.221 | |
= | $2,939.22 |
Denali Therapeutics's Market Cap for the quarter that ended in Dec. 2024 is calculated as
Market Cap (Q: Dec. 2024 ) | = | Share Price (Q: Dec. 2024 ) | * | Shares Outstanding (EOP) (Q: Dec. 2024 ) |
= | $20.38 | * | 144.221 | |
= | $2,939.22 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (NAS:DNLI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Denali Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Carole Ho | officer: Chief Medical Officer | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Alexander O. Schuth | officer: COO and Secretary | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Steve E. Krognes | officer: CFO and Treasurer | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Ryan J. Watts | director, officer: President and CEO | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Vicki L Sato | director | 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
David P Schenkein | director | C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Jennifer E. Cook | director | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Marc Tessier-lavigne | director | 1 DNA WAY, SOUTH SAN FRANCISCO CA 94080 |
Erik Harris | director | 60 LEVERONI COURT, NOVATO CA 94949 |
Douglas K Bratton | 10 percent owner | 201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102 |
Nancy Thornberry | director | SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036 |
Biogen Inc. | 10 percent owner | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Biogen Ma Inc. | 10 percent owner | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Clinton Bybee | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Robert Nelsen | director, 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By Marketwired • 05-07-2024
By Marketwired • 08-01-2024
By Marketwired • 01-30-2025
By Marketwired • 01-06-2025
By GuruFocus Research • 05-07-2024
By GuruFocus News • 01-08-2025
By GuruFocus News • 11-13-2024
By Marketwired • 06-03-2024
By GuruFocus Research • 02-27-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.